A cell based coronavirus vaccine is being developed by Heat Biologics in collaboration with University of Miami for the treatment and prevention of COVID-2019 infections using its gp96 vaccine platform. The vaccine expresses the Spike or S protein, gp96 and OX40L, a T cell co-stimulator. OX40L co-stimulation expands CD4+ helper T cells that promote B-cell differentiation and IgG/IgA antibody class switching. The vaccine is designed to clear virus infected cells by promoting long-term cellular immunity, essential for preventing the spread of re-infection in susceptible individuals such as the elderly and other high-risk patients with relevant comorbidities. Preclinical development is underway in the US.
Heat shock protein gp96 is a ubiquitous protein found in all human cells and also known as the immune system's swiss army knife due to its function as a potent immune adjuvant playing the role of molecular warning system to induce immunity against necrotic cells. Heat's proprietary gp96 vaccine platform reprograms live cells to continually secrete antigens of interest bound to the gp96, thus activating a robust T-cell response against those antigens. Heat's gp96 vaccine platform activates CD8 T cells, antigen presenting cells and natural killer cells, and induces mucosal immunity that can provide protection against COVID-19 infections.
In May 2020, Heat Biologics and Waisman Biomanufacturing entered into a manufacturing agreement to manufacture COVID-19 vaccine. According to the agreement, Waisman will support the manufacturing of COVID-19 vaccine for expected phase I clinical trials. 
In March 2020, Heat Biologics entered into a strategic collaboration with the University of Miami Miller School of Medicine to support the development of a vaccine leveraging Heat's proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19. Under the terms of the research collaboration, University of Miami will develop and test one or more vaccine constructs utilizing Heat's gp-96 vaccine backbone to express antigens associated with COVID-19. 
Key Development Milestones
As of March 2020, preclinical development of the corona virus vaccine is underway in the US  .
Heat Biologics announced that it has filed a provisional patent for use of its technology platform for treating or preventing infection with the SARS-CoV-2 virus that causes coronavirus disease 2019 (COVID-19)  .